Loading...
Loading...
Depomed, Inc.
DEPO announced today that GRALISE^ tablets are now
available as a new once-daily treatment for postherpetic neuralgia, the
pain following healing of the rash associated with shingles. GRALISE is
available by prescription in a 30-day starter pack, which allows titration of
the drug to full dose in 15 days, as well as bottles of 600 mg and 300 mg
tablets. GRALISE is a proprietary formulation of gabapentin, using patented
polymer technology that enables gradual release of the drug. GRALISE has a
favorable safety profile. GRALISE has no branded or generic equivalent and is
not interchangeable with other gabapentin products.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in